Bioscience Investment Associate
Wenping is responsible for evaluating biotech company investment opportunities, conducting due diligence, and managing portfolio companies. She joined CI after finishing her Ph.D. in cell biology at Yale University, where she examined the biological roots of blood vessel development using optogenetics, single-cell RNA sequencing, proteomics, CRISPR gene editing technologies, and so on.
While at Yale, Wenping co-led a pro bono consulting project for a biotech company to identify promising disease areas for them to discover potential biomarkers. Interested in exploring bioscience investment, she served as a venture fellow at Alumni Ventures Group (Blue Ivy Ventures) and did part-time internships with Lilly Asia Ventures and Simcere Pharmaceutical Group.